The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review
暂无分享,去创建一个
[1] J. Ruidavets,et al. Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study , 2016, BMC Medicine.
[2] M. Banach,et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate , 2016, BMC Medicine.
[3] Alberto Revelli,et al. Cancer and fertility preservation: international recommendations from an expert meeting , 2016, BMC Medicine.
[4] Yuan-Lin Guo,et al. Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease , 2016, Medicine.
[5] M. Banach,et al. Lipids, blood pressure and kidney update 2015 , 2015, Lipids in Health and Disease.
[6] C. Aguayo,et al. Apolipoprotein A-I enhances proliferation of human endothelial progenitor cells and promotes angiogenesis through the cell surface ATP synthase. , 2015, Microvascular research.
[7] M. Nakata,et al. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia , 2015, Lipids in Health and Disease.
[8] S. Najib,et al. Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins. , 2015, Atherosclerosis.
[9] Ying-jian Liang,et al. Reciprocal activation between ATPase inhibitory factor 1 and NF‐κB drives hepatocellular carcinoma angiogenesis and metastasis , 2014, Hepatology.
[10] M. Banach,et al. Subfractions and subpopulations of HDL: an update. , 2014, Current medicinal chemistry.
[11] M. Banach,et al. Should low high-density lipoprotein cholesterol (HDL-C) be treated? , 2014, Best practice & research. Clinical endocrinology & metabolism.
[12] F. Portillo,et al. Differential Role of Snail1 and Snail2 Zinc Fingers in E-cadherin Repression and Epithelial to Mesenchymal Transition* , 2013, The Journal of Biological Chemistry.
[13] J. Ruidavets,et al. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study[S] , 2013, Journal of Lipid Research.
[14] M. Banach,et al. An update on biomarkers of heart failure in hypertensive patients , 2012, Journal of hypertension.
[15] Masasuke Yoshida,et al. Assessing Actual Contribution of IF1, Inhibitor of Mitochondrial FoF1, to ATP Homeostasis, Cell Growth, Mitochondrial Morphology, and Cell Viability* , 2012, The Journal of Biological Chemistry.
[16] C. Seiler,et al. The impact of the coronary collateral circulation on mortality: a meta-analysis. , 2012, European heart journal.
[17] J. Ruidavets,et al. Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum and Is Positively Correlated with HDL-Cholesterol , 2011, PloS one.
[18] A. Ventosa,et al. A Novel Halophilic Lipase, LipBL, Showing High Efficiency in the Production of Eicosapentaenoic Acid (EPA) , 2011, PloS one.
[19] A. Ortega,et al. Up-regulation of the ATPase Inhibitory Factor 1 (IF1) of the Mitochondrial H+-ATP Synthase in Human Tumors Mediates the Metabolic Shift of Cancer Cells to a Warburg Phenotype* , 2010, The Journal of Biological Chemistry.
[20] M. Duchen,et al. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. , 2008, Cell metabolism.
[21] S. Pizzo,et al. An Inhibitor of the F1 Subunit of ATP Synthase (IF1) Modulates the Activity of Angiostatin on the Endothelial Cell Surface* , 2004, Journal of Biological Chemistry.
[22] F. Bosetti,et al. Myocardial ischemic preconditioning and mitochondrial F1F0-ATPase activity , 2000, Molecular and Cellular Biochemistry.
[23] I. Hassinen,et al. Role of cellular energetics in ischemia-reperfusion and ischemic preconditioning of myocardium , 1998, Molecular and Cellular Biochemistry.
[24] Xavier Collet,et al. Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis , 2003, Nature.
[25] E. Carver,et al. The Mouse Snail Gene Encodes a Key Regulator of the Epithelial-Mesenchymal Transition , 2001, Molecular and Cellular Biology.
[26] T. L. Moser,et al. Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Rigotti,et al. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism , 2000, Current opinion in lipidology.
[28] G. Grover,et al. Preconditioning in rat hearts is independent of mitochondrial F1F0 ATPase inhibition. , 1998, The American journal of physiology.
[29] G. Grover,et al. Preconditioning in rat hearts is independent of mitochondrial F1F0ATPase inhibition. , 1998, American journal of physiology. Heart and circulatory physiology.
[30] J. M. Izquierdo,et al. Subcellular structure containing mRNA for beta subunit of mitochondrial H+-ATP synthase in rat hepatocytes is translationally active. , 1997, The Biochemical journal.
[31] William Rouslin,et al. IF1 Function in Situ in Uncoupler-challenged Ischemic Rabbit, Rat, and Pigeon Hearts* , 1996, The Journal of Biological Chemistry.
[32] K. Altendorf,et al. The F0F1-type ATP synthases of bacteria: structure and function of the F0 complex. , 1996, Annual review of microbiology.
[33] I. Hassinen,et al. Mechanisms of ischemic preconditioning in rat myocardium. Roles of adenosine, cellular energy state, and mitochondrial F1F0-ATPase. , 1995, Circulation.
[34] N. Vázquez-Laslop,et al. The native F0F1-inhibitor protein complex from beef heart mitochondria and its reconstitution in liposomes , 1995, Journal of bioenergetics and biomembranes.
[35] A. Das,et al. Reversible modulation of the mitochondrial ATP synthase with energy demand in cultured rat cardiomyocytes , 1989, FEBS letters.
[36] S. Papa,et al. Regulatory role of the ATPase inhibitor protein on proton conduction by mitochondrial H+‐ATPase complex , 1987, FEBS letters.